Clinical exacerbation of SARS-CoV2 infection after fingolimod withdrawal

被引：26
作者：
Gomez-Mayordomo, Victor [1 ]
Montero-Escribano, Paloma [1 ]
Matias-Guiu, Jordi A. [1 ]
Gonzalez-Garcia, Nuria [1 ]
Porta-Etessam, Jesus [1 ]
Matias-Guiu, Jorge [1 ]
机构：
[1] Univ Complutense, Hosp Clin San Carlos, San Carlos Hlth Res Inst IdISSC, Dept Neurol,Inst Neurosci, Prof Martin Lagos S-N, Madrid 28040, Spain
来源：
JOURNAL OF MEDICAL VIROLOGY | 2021年 / 93卷 / 01期
关键词：
coronavirus; COVID-19; exacerbation; fingolimod; multiple sclerosis; SARS-CoV-2; MULTIPLE-SCLEROSIS; REBOUND SYNDROME;
D O I：
10.1002/jmv.26279
中图分类号：
Q93 [微生物学];
学科分类号：
071005 ; 100705 ;
摘要：
The role of disease-modifying therapies in patients with autoimmune disorders during severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) infection is controversial. Immunocompromised patients could have a more severe coronavirus disease-2019 (COVID-19) due to the absence of an adequate immune response against the SARS-CoV-2. However, therapies that act on immune response could play a protective role by dampening the cytokine-release syndrome. Fingolimod is a drug used for immune therapy in patients with multiple sclerosis (MS) through the sequestration of activated lymphocytes in the lymph nodes. We report the case of a 57-year-old man with relapsing-remitting MS treated with fingolimod that showed a reactivation of COVID-19 with signs of hyperinflammation syndrome after fingolimod withdrawal. Our case suggests that discontinuation of fingolimod during COVID-19 could imply a worsening of SARS-CoV2 infection.
引用
收藏
页码：546 / 549
页数：4
相关论文
共 19 条
[1]  
Andrade C, 2016, JAMA NEUROL, V73, P1375, DOI 10.1001/jamaneurol.2016.3507
[2]   The underpinning biology relating to multiple sclerosis disease modifying treatments during the COVID-19 pandemic [J].
Baker, David ;
Amor, Sandra ;
Kang, Angray S. ;
Schmierer, Klaus ;
Giovannoni, Gavin .
MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2020, 43
[3]   COVID-19 infection in a patient with multiple sclerosis treated with fingolimod [J].
Barzegar, Mahdi ;
Mirmosayyeb, Omid ;
Nehzat, Nasim ;
Sarrafi, Reza ;
Khorvash, Farzin ;
Maghzi, Amir-Hadi ;
Shaygannejad, Vahid .
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION, 2020, 7 (04)
[4]   2 CORONAVIRUSES ISOLATED FROM CENTRAL NERVOUS-SYSTEM TISSUE OF 2 MULTIPLE-SCLEROSIS PATIENTS [J].
BURKS, JS ;
DEVALD, BL ;
JANKOVSKY, LD ;
GERDES, JC .
SCIENCE, 1980, 209 (4459) :933-934
[5]   Dysregulation of sphingosine 1 phosphate receptor-1 (S1P1) signaling and regulatory lymphocyte-dependent immunosuppression in a model of post-fingorimod MS rebound [J].
Cavone, Leonardo ;
Felici, Roberta ;
Lapucci, Andrea ;
Buonvicino, Daniela ;
Pratesi, Sara ;
Muzzi, Mirko ;
Hakiki, Bahia ;
Maggi, Laura ;
Peruzzi, Benedetta ;
Caporale, Roberto ;
Annunziato, Francesco ;
Amato, Maria Pia ;
Chiarugi, Alberto .
BRAIN BEHAVIOR AND IMMUNITY, 2015, 50 :78-86
[6]   COVID-19: Consider IL-6 receptor antagonist for the therapy of cytokine storm syndrome in SARS-CoV-2 infected patients [J].
Chakraborty, Chiranjib ;
Sharma, Ashish Ranjan ;
Bhattacharya, Manojit ;
Sharma, Garima ;
Lee, Sang-Soo ;
Agoramoorthy, Govindasamy .
JOURNAL OF MEDICAL VIROLOGY, 2020, 92 (11) :2260-2262
[7]   Immunologic characterization of a immunosuppressed multiple sclerosis patient that recovered from SARS-CoV-2 infection [J].
Chiarini, Marco ;
Paghera, Simone ;
Moratto, Daniele ;
De Rossi, Nicola ;
Giacomelli, Mauro ;
Badolato, Raffaele ;
Capra, Ruggero ;
Imberti, Luisa .
JOURNAL OF NEUROIMMUNOLOGY, 2020, 345
[8]   Severe COVID-19 infection in a patient with multiple sclerosis treated with fi ngolimod [J].
Foerch, Christian ;
Friedauer, Lucie ;
Bauer, Boris ;
Wolf, Timo ;
Adam, Elisabeth H. .
MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2020, 42
[9]   Anti-CD20 immunosuppressive disease-modifying therapies and COVID-19 [J].
Giovannoni, Gavin .
MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2020, 41
[10]   The COVID-19 pandemic and the use of MS disease-modifying therapies [J].
Giovannoni, Gavin ;
Hawkes, Chris ;
Lechner-Scott, Jeannette ;
Levy, Michael ;
Waubant, Emmanuelle ;
Gold, Julian .
MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2020, 39
12